ERBB2 and breast cancer: For example, PTEN loss is frequent in many tumor types and is associated with sensitivity to PI3K inhibitors [12], whereas human epidermal growth receptor 2 (HER2) amplification in breast cancer is tested for guiding HER2 targeted therapy [13].